Latest Capital Raises News

Constellation Resources advances its exploration in Western Australia with encouraging natural hydrogen and copper-gold findings, supported by CSIRO studies and a $2.1 million capital raise.

Omni Bridgeway reported a strong start to FY26 with A$136.6 million in cash investment proceeds and a robust pipeline of nearly A$318 million in potential new commitments. The company also settled a long-standing legal liability and is progressing well with fund capital raising.

Elixinol Wellness reported steady Q3 revenue with a notable 300bps gross margin improvement, driven by e-commerce and core brands, while executing cost reduction initiatives supported by a $2.5 million capital raise.

Terrain Minerals has raised $1.17 million through a placement to fund further drilling at its promising Smokebush Project, targeting high-grade gold and silver deposits.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

Artemis Resources has reported promising early drilling results at its Karratha Gold-Copper Project alongside key tenement grants and agreements at its Cassowary Exploration Project, supported by a recent $4.9 million capital raise.

Tasman Resources has progressed its exploration efforts at Lake Torrens and Parkinson Dam projects, backed by a recent $850,000 capital raise and strategic board changes.

Great Divide Mining has poured its first gold at the Challenger Gold Mine, marking a key milestone as it moves from exploration to production. The company raised $1.335 million to support its ramp-up plans amid ongoing joint venture challenges.

Peregrine Gold has identified large-scale, high-grade iron ore deposits at its Newman project and expanded gold anomalies at Tin Can and Epithermal prospects, backed by a $3 million capital raise.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.